Stay updated on Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    A minor site revision tag (Revision: v3.4.2) was added, and the previous government funding notice about updates and operations was removed. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-11T02:39:51.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice about government funding lapse and NIH operations was added, and the page revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-02-03T23:48:32.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Added a Show glossary option, added Last Update Submitted that Met QC Criteria, added No FEAR Act Data, and updated Revision: v3.4.0; removed Last Update Submitted that met QC Criteria, removed No FEAR Act data, and removed Revision: v3.3.4.
    Difference
    0.2%
    Check dated 2026-01-27T23:57:27.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and v3.3.3 was removed; there are no changes to the study details, eligibility criteria, locations, or primary/secondary outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-14T01:46:12.000Z thumbnail image
  6. Check
    64 days ago
    Change Detected
    Summary
    Locations section now consolidates and lists participating sites by state (Arizona, California, Florida, Iowa, Massachusetts, Minnesota, Mississippi, New York, North Carolina, Ohio, Oregon, Rhode Island, Tennessee, Texas, Virginia). The HHS Vulnerability Disclosure link was removed and the page revision is updated to v3.3.3.
    Difference
    1%
    Check dated 2025-12-23T08:14:57.000Z thumbnail image
  7. Check
    85 days ago
    Change Detected
    Summary
    Footer revision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2025-12-01T16:49:45.000Z thumbnail image

Stay in the know with updates to Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Niraparib + Dostarlimab in Platinum Resistant Ovarian Cancer Clinical Trial page.